Nanocapsules generated out of a polymeric dexamethasone shell suppress the inflammatory response of liver macrophages

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 8, 2013, Pages 1223-1234

  Fichter, Michael ^a   Baier, Grit ^b   Dedters, Marvin ^a   Pretsch, Leah ^a   Pietrzak Nguyen, Anette ^a   Landfester, Katharina ^b   Gehring, Stephan ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

Author keywords

Cytokines; Dexamethasone nanocapsules; Kupffer cells; Liver sinusoid endothelial cells

Indexed keywords

ANTI-INFLAMMATORIES; CYTOKINES; DEXAMETHASONES; HYDROXYETHYL STARCHES; INFLAMMATORY CELLS; INFLAMMATORY CYTOKINES; INFLAMMATORY RESPONSE; KUPFFER CELLS;

CYTOLOGY; ENDOTHELIAL CELLS; LIVER; MACROPHAGES; NANOCAPSULES; POLYMERS; STEROID HORMONES;

DRUG PRODUCTS;

DEXAMETHASONE; GLUCOSE POLYMER; INTERLEUKIN 6; NANOCAPSULE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; INFLAMMATION; KUPFFER CELL; MOUSE; NONHUMAN; PHAGOCYTE; TARGET CELL;

MURINAE;

CYTOKINES; DEXAMETHASONE NANOCAPSULES; KUPFFER CELLS; LIVER SINUSOID ENDOTHELIAL CELLS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CYTOKINES; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; FEMALE; HYDROXYETHYL STARCH DERIVATIVES; KUPFFER CELLS; MICE; MICE, INBRED C57BL; NANOCAPSULES;

EID: 84886383153     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.05.005     Document Type: Article

References (46)

1. Liu S.Q., Tong Y.W., Yang Y.Y. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly(D, L-lactide-co-glycolide) with varying compositions. Biomaterials 2005, 26(24):5064-5074.
2. Nanjwade B.K., Bechra H.M., Derkar G.K., Manvi F.V., Nanjwade V.K. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009, 38(3):185-196.
3. Yellepeddi V.K., Kumar A., Palakurthi S. Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. Anticancer Res 2009, 29(8):2933-2943.
4. Musacchio T., Torchilin V.P. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci 2011, 16:1388-1412.
5. Zhang S.F., Uludag H. Nanoparticulate systems for growth factor delivery. Pharm Res 2009, 26(7):1561-1580.
6. Landfester K. Miniemulsionspolymerisation und struktur von polymer- und hybridnanopartikeln. Angewandte Chemie 2009, 121(25):4556-4576.
7. Landfester K., Musyanovych A., Mailander V. From polymeric particles to multifunctional nanocapsules for biomedical applications using the miniemulsion process. Journal of Polymer Science Part a-Polymer Chemistry 2010, 48(3):493-515.
8. Baier G., Musyanovych A., Mailaender V., Landfester K. Performing encapsulation of dsDNA and a polymerase chain reaction (PCR) inside nanocontainers using the inverse miniemulsion process. Int J Artif Organs 2012, 35(1):77-83.
9. Meikle A.W., Tyler F.H. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977, 63(2):200-207.
10. Doyle L.W., Ehrenkranz R.A., Halliday H.L. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010, 98(3):217-224. [Epub 2010/04/15].
11. Gomez-Gaete C., Tsapis N., Besnard M., Bochot A., Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007, 331(2):153-159. [Epub 2006/12/13].
12. Da Silva G.R., Ayres E., Orefice R.L., Moura S.A., Cara D.C., Cunha Ada S. Controlled release of dexamethasone acetate from biodegradable and biocompatible polyurethane and polyurethane nanocomposite. J Drug Target 2009, 17(5):374-383. [Epub 2009/06/27].
13. Fratoddi I., Venditti I., Cametti C., Palocci C., Chronopoulou L., Marino M., et al. Functional polymeric nanoparticles for dexamethasone loading and release. Colloids Surf B Biointerfaces 2012, 93:59-66. [Epub 2012/01/10].
14. Krishnan V., Xu X., Barwe S.P., Yang X., Czymmek K., Waldman S.A., et al. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. Mol Pharm 2012, [Epub 2012/12/01].
15. Melgert B.N., Olinga P., Van Der Laan J.M., Weert B., Cho J., Schuppan D., et al. Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001, 34(4 Pt 1):719-728. [Epub 2001/10/05].
16. Wang M.T., Jin Y., Yang Y.X., Zhao C.Y., Yang H.Y., Xu X.F., et al. In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system. Int J Nanomedicine 2010, 5:487-497. [Epub 2010/10/20].
17. Marchant R.E., Yuan S., Szakalasgratzl G. Interactions of plasma-proteins with a novel polysaccharide surfactant physisorbed to polyethylene. J Biomater Sci Polym Ed 1994, 6(6):549-564.
18. Osterberg E., Bergstrom K., Holmberg K., Schuman T.P., Riggs J.A., Burns N.L., et al. Protein-rejecting ability of surface-bound dextran in end-on and side-on configurations - comparison to PEG. J Biomed Mater Res 1995, 29(6):741-747.
19. Kraft D., Sirtl C., Laubenthal H., Scheiner O., Parth E., Dieterich H.J., et al. No evidence for the existence of preformed antibodies against hydroxyethyl starch in man. Eur Surg Res 1992, 24(3):138-142.
20. Treib J., Baron J.F. Hydroxyethyl starches: effects on haemostasis. Annales Francaises D Anesthesie Et De Reanimation 1998, 17(1):72-81.
21. Joshi M.D., Muller R.H. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009, 71(2):161-172. [Epub 2008/10/01].
22. Ishibashi H., Nakamura M., Komori A., Migita K., Shimoda S. Liver architecture, cell function, and disease. Semin Immunopathol 2009, 31(3):399-409. [Epub 2009/05/27].
23. Racanelli V., Rehermann B. The liver as an immunological organ. Hepatology 2006, 43(2 Suppl 1):S54-S62. [Epub 2006/02/01].
24. Schlaad H., Kukula H., Rudloff J., Below I. Synthesis of alpha, omega-heterobifunctional poly(ethylene glycol)s by metal-free anionic ring-opening polymerization. Macromolecules 2001, 34(13):4302-4304.
25. Crespy D.M.A., Landfester K. Synthesis of polymer particles and nanocapsules stabilized with PEO/PPO containing polymerizable surfactants in miniemulsion. Colloid Polym Sci 2006, 284(7):8.
26. Gehring S., Dickson E.M., San Martin M.E., van Rooijen N., Papa E.F., Harty M.W., et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 2006, 130(3):810-822. [Epub 2006/03/15].
27. Gregory S.H., Wing E.J. Neutrophil-Kupffer cell interaction: a critical component of host defenses to systemic bacterial infections. J Leukoc Biol 2002, 72(2):239-248. [Epub 2002/08/01].
28. Parker G.A., Picut C.A. Liver immunobiology. Toxicol Pathol 2005, 33(1):52-62. [Epub 2005/04/05].
29. Tan H.H., Fiel M.I., Sun Q., Guo J., Gordon R.E., Chen L.C., et al. Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease. J Immunotoxicol 2009, 6(4):266-275. [Epub 2009/11/17].
30. Mendes F., Couto C.A., Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011, 15(4):859-878. [Epub 2011/10/29].
31. Mieli-Vergani G., Vergani D. Autoimmune liver diseases in children - what is different from adulthood?. Best Pract Res Clin Gastroenterol 2011, 25(6):783-795. [Epub 2011/11/29].
32. London N.J., Chiang A., Haller J.A. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011, 28(5):351-366. [Epub 2011/04/16].
33. Meyers R.L., Book L.S., O'Gorman M.A., Jackson W.D., Black R.E., Johnson D.G., et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. J Pediatr Surg 2003, 38(3):406-411. [Epub 2003/03/13].
34. Hegeman M.A., Cobelens P.M., Kamps J., Hennus M.P., Jansen N.J., Schultz M.J., et al. Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br J Pharmacol 2011, 163(5):1048-1058. [Epub 2011/03/12].
35. Ogilvie MP, Pereira BM, McKenney MG, McMahon PJ, Manning RJ, Namias N, et al. First report on safety and efficacy of hetastarch solution for initial fluid resuscitation at a level 1 trauma center. J Am Coll Surg. 2010;210(5):870-80, 80-2. Epub 2010/04/28.
36. Lissauer M.E., Chi A., Kramer M.E., Scalea T.M., Johnson S.B. Association of 6% hetastarch resuscitation with adverse outcomes in critically ill trauma patients. Am J Surg 2011, 202(1):53-58. [Epub 2011/05/24].
37. Arnold M., Rutter W.J. Liver amylase. III. Synthesis by the perfused liver and secretion into the perfusion medium. J Biol Chem 1963, 238:2760-2765. [Epub 1963/08/01].
38. Dubuisson L., Bioulac-Sage P., Boussarie L., Quinton A., Saric J., de Mascarel A., et al. Removal of cellular debris formed in the Disse space in patients with cholestasis. Virchows Arch A Pathol Anat Histopathol 1987, 410(6):501-507. [Epub 1987/01/01].
39. van Kooten C, Stax AS, Woltman AM, Gelderman KA. Handbook of experimental pharmacology "dendritic cells": the use of dexamethasone in the induction of tolerogenic DCs. 2009;188:233-49.
40. Baier G., Baumann D., Siebert J.M., Musyanovych A., Mailander V., Landfester K. Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. Biomacromolecules 2012, [Epub 2012/08/01].
41. Connolly M.K., Bedrosian A.S., Malhotra A., Henning J.R., Ibrahim J., Vera V., et al. In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity. J Immunol 2010, 185(4):2200-2208. [Epub 2010/07/20].
42. Knolle P.A., Limmer A. Control of immune responses by savenger liver endothelial cells. Swiss Med Wkly 2003, 133(37-38):501-506. [Epub 2003/12/04].
43. Klein I., Cornejo J.C., Polakos N.K., John B., Wuensch S.A., Topham D.J., et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 2007, 110(12):4077-4085. [Epub 2007/08/11].
44. Roberts R.A., Ganey P.E., Ju C., Kamendulis L.M., Rusyn I., Klaunig J.E. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007, 96(1):2-15. [Epub 2006/11/24].
45. Kolios G., Valatas V., Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006, 12(46):7413-7420. [Epub 2006/12/15].
46. Gehring S., Sabo E., San Martin M.E., Dickson E.M., Cheng C.W., Gregory S.H. Laser capture microdissection and genetic analysis of carbon-labeled Kupffer cells. World J Gastroenterol 2009, 15(14):1708-1718. [Epub 2009/04/11].